Exhibit 99.3

Unaudited Pro Forma Condensed Combined Financial Statements of Endo Pharmaceuticals Holdings Inc.

On June 17, 2011, Endo Pharmaceuticals Holdings Inc. completed the acquisition of American Medical Systems Holdings, Inc. (“AMS”) for approximately $2.4 billion in aggregate consideration, including $2.3 billion in cash paid for equity, $71.6 million related to existing AMS stock-based compensation awards and certain other amounts, at which time AMS became a wholly-owned subsidiary of the Company. AMS’s shares were purchased at a price of $30.00 per share.

The acquisition has been accounted for as a business combination (in accordance with ASC 805 Business Combinations) and, as such, the AMS assets acquired and liabilities assumed have been recorded at their respective fair values. The determination of fair value for the identifiable tangible and intangible assets acquired and liabilities assumed requires extensive use of accounting estimates and judgments. Significant estimates and assumptions include, but are not limited to: determining the timing and estimated costs to complete the in-process research and development projects, projecting the likelihood and timing of obtaining regulatory approval, estimating future cash flows and determining the appropriate discount rate. The estimated fair values of the assets acquired and liabilities assumed on the AMS acquisition date included in the Unaudited Pro Forma Condensed Combined Financial Statements (the “Statements”) are provisional.

As used herein, the terms “the Company,” “we,” and “our” refer to Endo Pharmaceuticals Holdings Inc., and, where applicable, its consolidated subsidiaries. The Unaudited Pro Forma Condensed Combined Balance Sheet as of March 31, 2011 gives effect to the AMS Acquisition as if it had occurred on that date and includes historical data as reported by the separate companies as well as adjustments that give effect to events that are directly attributable to the AMS Acquisition, including the additional term loan indebtedness established and senior note financing issued in connection with the acquisition of AMS, and that are factually supportable. The Unaudited Pro Forma Condensed Combined Statements of Operations for the three months ended March 31, 2011 and for the year ended December 31, 2010 give effect to the AMS Acquisition as if it had been consummated on January 1, 2010 and include historical data as reported by the separate companies as well as adjustments that give effect to events that are directly attributable to the AMS Acquisition, including the additional term loan indebtedness established and senior note financing issued in connection with the acquisition of AMS, are expected to have a continuing impact and that are factually supportable.

The pro forma adjustments reflecting the consummation of the AMS Acquisition are based upon the acquisition method of accounting in accordance with U.S. generally accepted accounting principles and upon the assumptions set forth in the Notes included in this section. The Statements have been prepared based on available information, using estimates and assumptions that our management believes are reasonable. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates and assumptions are preliminary and have been made solely for purposes of developing this unaudited pro forma condensed combined financial information. The Unaudited Pro Forma Condensed Combined Balance Sheet has been adjusted to reflect the allocation of the purchase price to identifiable net assets acquired and of the excess purchase price to goodwill.

The Unaudited Pro Forma Condensed Combined Statements of Operations do not purport to represent the actual results of operations that would have occurred if the acquisition had taken place on the date specified and are not necessarily indicative of the results of operations that may be achieved in the future. The Unaudited Pro Forma Condensed Combined Statements of Operations do not reflect any adjustments for the effect of non-recurring items or operating synergies that we may realize as a result of the acquisition. The Unaudited Pro Forma Condensed Combined Statements of Operations include certain reclassifications to conform the historical financial information of AMS to our presentation.

The assumptions used and adjustments made in preparing the Statements are described in the Notes, which should be read in conjunction with the Statements. The Statements and related Notes contained herein should be read in conjunction with the Consolidated Financial Statements and related Notes included in our Annual Report on Form 10-K for the year ended December 31, 2010 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as well as the Consolidated Financial Statements and related Notes included in AMS’s Annual Report on Form 10-K for the year ended January 1, 2011 and AMS’s Quarterly Report on Form 10-Q for the fiscal quarter ended April 2, 2011.

1

ENDO PHARMACEUTICALS HOLDINGS INC.

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

AS OF MARCH 31, 2011

(In thousands)

2

ENDO PHARMACEUTICALS HOLDINGS INC.

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2011

(In thousands, except per share data)

3

ENDO PHARMACEUTICALS HOLDINGS INC.

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2010

(In thousands, except per share data)

4

ENDO PHARMACEUTICALS HOLDINGS INC.

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Note 1. Basis of pro forma presentation

The Unaudited Pro Forma Condensed Combined Balance Sheet combines our Consolidated Balance Sheet as of March 31, 2011 with the Consolidated Balance Sheet of AMS as of April 2, 2011.

The Unaudited Pro Forma Condensed Combined Statement of Operations for the three months ended March 31, 2011 combines the three months ended March 31, 2011 for Endo with the three months ended April 2, 2011 for AMS.

The Unaudited Pro Forma Condensed Combined Statement of Operations for the year ended December 31, 2010 combines the year ended December 31, 2010 for Endo with the year ended January 1, 2011 for AMS.

The Unaudited Pro Forma Condensed Combined Statements of Operations do not reflect the non-recurring expenses that we expect to incur in connection with the AMS transaction, including fees to investment bankers, attorneys, accountants and other professional advisors, the write-off of deferred financing costs, and other transaction-related costs that will not be capitalized, excluding debt issuance costs. Additionally, the Unaudited Pro Forma Condensed Combined Statements of Operations do not reflect the effects of any anticipated cost savings and any related non-recurring costs to achieve those cost savings. The Unaudited Pro Forma Condensed Combined Statements of Operations do not purport to represent our actual results of operations that would have occurred if the acquisitions had taken place on the dates specified, nor are they necessarily indicative of the results of operations that may be achieved in the future. The Unaudited Pro Forma Condensed Combined Statements of Operations include certain reclassifications to conform the historical financial information of AMS to our financial presentation.

The acquisition-date fair value of the consideration transferred totalled $2.4 billion and consisted of the following items (in thousands):

Assuming an acquisition date of March 31, 2011, the purchase price of AMS would have been allocated to the following assets and liabilities (in thousands):

5

The above estimated fair values of assets acquired and liabilities assumed are provisional and are based on the information that was available to estimate the fair value of assets acquired and liabilities assumed. We believe that this information provides a reasonable basis for estimating the fair values but we are waiting for additional information necessary to finalize those amounts. Thus, the provisional measurements of fair value reflected are subject to change. Such changes could be significant. We expect to finalize our purchase price allocation as soon as practicable but no later than one year from the closing date of the AMS acquisition.

An allocation of an increased portion of the purchase price to inventory, property, plant and equipment, other noncurrent assets and/or to identifiable intangible assets will reduce the amount of the purchase price allocated to goodwill in the unaudited condensed financial information, and may result in increased depreciation and/or amortization expense.

Prior to the AMS acquisition, AMS incurred transaction costs of $31.8 million. These costs were reflected in our purchase price allocation table above as a reduction to cash of $27.0 million, representing the entire AMS cash and cash equivalents balance at March 31, 2011. The remaining transaction costs were recorded as an increase to accrued expenses.

The acquired finite-lived intangible assets are being amortized over the estimated useful life in proportion to the economic benefits consumed, which, for purposes of this presentation, is approximated by using the straight-line method.

Note 2. Pro forma adjustments

6

Amortization related to the value of definite-lived intangible assets is reflected as pro forma adjustments to the Unaudited Pro Forma Condensed Combined Statements of Operations.

The fair value of the developed technology, in-process research and development and customer relationship assets were estimated using a discounted present value income approach. Under this method, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows (excess earnings) attributable solely to the intangible asset over its remaining useful life. To calculate fair value, the Company

7

used cash flows discounted at rates considered appropriate given the inherent risks associated with each type of asset. The Company believes that the level and timing of cash flows appropriately reflect market participant assumptions. The fair value of the AMS and GreenLight tradenames were estimated using an income approach, specifically known as the relief from royalty method. The relief from royalty method is based on a hypothetical royalty stream that would be received if the Company were to license the AMS or GreenLight tradename. Thus, we derived the hypothetical royalty income from the projected revenues of AMS and GreenLight products, respectively. Cash flows were assumed to extend through the remaining economic useful life of each class of intangible asset.

These provisional measurements of fair value reflected are subject to change. Such changes could be significant.

The amount of the adjustment to Other assets reflects the increase in debt issuance costs of $80.3 million (see 2a) related to fees paid to borrow the $3.1 billion that are required to be capitalized, net of $4.1 million of AMS’s existing unamortized debt issuance costs required to be written off in accordance with the applicable accounting guidance for business combinations and $9.0 million of Endo’s existing unamortized debt issuance costs required to be written off as a loss on extinguishment of debt in accordance with the applicable accounting guidance for debt modifications and extinguishments.

These deferred debt issuance costs will be amortized over the life of the related debt instruments, with maturities ranging from 2016 to 2022. The amortization of debt issuance costs is reflected as a pro forma adjustment to the Unaudited Pro Forma Condensed Combined Statements of Operations.

8

Amortization expense related to developed technology and tradenames is classified as Cost of revenues, which is consistent with our historical caption presentation of this expense. Amortization expense related to customer relationships is classified as Selling, general and administrative expense. These provisional measurements of fair value reflected are subject to change. Such changes could be significant.

9

The net adjustments for the three months ended March 31, 2011 and the year ended December 31, 2010 consist of the following components (in thousands), assuming new financing consisting of (i) $1.5 billion aggregate principal amount of Term Loan A, (ii) $0.7 billion aggregate principal amount of Term Loan B and (iii) $0.9 billion aggregate principal amount of senior notes:

The portion of this adjustment related to the elimination of AMS’s interest expense is included in Other (income) expense, net in the accompanying Unaudited Pro Forma Condensed Combined Statements of Operations. AMS has historically presented interest expense and amortization of financing costs as separate line items in its historical consolidated statement of operations, but as a component of total other expenses. Accordingly, these amounts have been recorded in Other (income) expense, net in the accompanying Unaudited Pro Forma Condensed Combined Statements of Operations to conform to Endo’s presentation.

On an as adjusted basis, after giving effect to the additional term loan indebtedness established and senior note financing issued in connection with the acquisition of AMS, as of March 31, 2011, our total aggregate principal amount of debt would have consisted of approximately $2.2 billion of floating-rate debt. Based on this amount, a 1% rise in interest rates would result in approximately $22 million in incremental annual interest expense.

10